A Phase II Trial of Surgery and Stereotactic Radiosurgery With Neoadjuvant Nivolumab and Ipilimumab in Patients With Surgically-resectable, Solid Tumor Brain Metastases
Latest Information Update: 28 Jul 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases
- Focus Therapeutic Use
Most Recent Events
- 13 Sep 2021 Status changed from recruiting to discontinued due to Poor enrollment.
- 19 Jul 2021 Planned number of patients changed from 40 to 20.
- 29 Sep 2020 Status changed from not yet recruiting to recruiting.